A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Summary SGN‐30, a chimeric anti‐CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). We conducted an open‐label, Phase II study to determine the safety and objective response rate of SGN‐30 in 79 pa...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	British journal of haematology Ročník 146; číslo 2; s. 171 - 179
Hlavní autoři:	Forero‐Torres, Andres, Leonard, John P., Younes, Anas, Rosenblatt, Joseph D., Brice, Pauline, Bartlett, Nancy L., Bosly, Andre, Pinter‐Brown, Lauren, Kennedy, Dana, Sievers, Eric L., Gopal, Ajay K.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Oxford, UK Blackwell Publishing Ltd 01.07.2009 Blackwell
Témata:	Adult Aged anaplastic large cell lymphoma anaplastic lymphoma kinase Antibodies, Anti-Idiotypic - blood Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antineoplastic Agents - administration & dosage anti‐CD30 antibody Biological and medical sciences Chimerin Proteins - blood Dose-Response Relationship, Drug Female Hematologic and hematopoietic diseases Hodgkin Disease - therapy Hodgkin lymphoma Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, Large-Cell, Anaplastic - drug therapy Male Medical sciences Middle Aged monoclonal antibody Young Adult Hematology anti-CD30 antibody Anaplastic cell lymphoma Hodgkin disease Malignant hemopathy Large cell lymphoma Monoclonal antibody Non Hodgkin lymphoma Treatment Lymphoproliferative syndrome Phase II trial anaplastic large cell lymphoma Anaplastic lymphoma kinase Cancer Hodgkin lymphoma
ISSN:	0007-1048, 1365-2141, 1365-2141
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Summary SGN‐30, a chimeric anti‐CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). We conducted an open‐label, Phase II study to determine the safety and objective response rate of SGN‐30 in 79 patients with refractory/recurrent HL (n = 38) or systemic ALCL (n = 41). Each course of SGN‐30 comprised 6 weekly intravenous infusions, followed by a 2‐week treatment‐free period. Patients had received a median of 3 (range 1–5) prior regimens of chemotherapy or systemic therapy. The initial 40 patients received 6 mg/kg weekly; the latter 39 patients received 12 mg/kg weekly. In the ALCL group, two patients achieved a complete response and five additional patients achieved a partial response, with response durations ranging from 27 to 1460+ d. No objective responses were observed in the HL group; however, 11 patients (29%) had stable disease (duration 62–242 days). Although adverse events were common, most were mild or moderate, and no specific pattern of adverse events was observed in either disease group. These results demonstrate that weekly administration of SGN‐30 is safe, with modest clinical activity in patients with ALCL.
AbstractList	SGN-30, a chimeric anti-CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). We conducted an open-label, Phase II study to determine the safety and objective response rate of SGN-30 in 79 patients with refractory/recurrent HL (n = 38) or systemic ALCL (n = 41). Each course of SGN-30 comprised 6 weekly intravenous infusions, followed by a 2-week treatment-free period. Patients had received a median of 3 (range 1-5) prior regimens of chemotherapy or systemic therapy. The initial 40 patients received 6 mg/kg weekly; the latter 39 patients received 12 mg/kg weekly. In the ALCL group, two patients achieved a complete response and five additional patients achieved a partial response, with response durations ranging from 27 to 1460+ d. No objective responses were observed in the HL group; however, 11 patients (29%) had stable disease (duration 62-242 days). Although adverse events were common, most were mild or moderate, and no specific pattern of adverse events was observed in either disease group. These results demonstrate that weekly administration of SGN-30 is safe, with modest clinical activity in patients with ALCL. SGN‐30, a chimeric anti‐CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). We conducted an open‐label, Phase II study to determine the safety and objective response rate of SGN‐30 in 79 patients with refractory/recurrent HL ( n = 38) or systemic ALCL ( n = 41). Each course of SGN‐30 comprised 6 weekly intravenous infusions, followed by a 2‐week treatment‐free period. Patients had received a median of 3 (range 1–5) prior regimens of chemotherapy or systemic therapy. The initial 40 patients received 6 mg/kg weekly; the latter 39 patients received 12 mg/kg weekly. In the ALCL group, two patients achieved a complete response and five additional patients achieved a partial response, with response durations ranging from 27 to 1460+ d. No objective responses were observed in the HL group; however, 11 patients (29%) had stable disease (duration 62–242 days). Although adverse events were common, most were mild or moderate, and no specific pattern of adverse events was observed in either disease group. These results demonstrate that weekly administration of SGN‐30 is safe, with modest clinical activity in patients with ALCL. SummarySGN-30, a chimeric anti-CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). We conducted an open-label, Phase II study to determine the safety and objective response rate of SGN-30 in 79 patients with refractory-recurrent HL (n = 38) or systemic ALCL (n = 41). Each course of SGN-30 comprised 6 weekly intravenous infusions, followed by a 2-week treatment-free period. Patients had received a median of 3 (range 1-5) prior regimens of chemotherapy or systemic therapy. The initial 40 patients received 6 mg-kg weekly; the latter 39 patients received 12 mg-kg weekly. In the ALCL group, two patients achieved a complete response and five additional patients achieved a partial response, with response durations ranging from 27 to 1460+ d. No objective responses were observed in the HL group; however, 11 patients (29%) had stable disease (duration 62-242 days). Although adverse events were common, most were mild or moderate, and no specific pattern of adverse events was observed in either disease group. These results demonstrate that weekly administration of SGN-30 is safe, with modest clinical activity in patients with ALCL. SGN-30, a chimeric anti-CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). We conducted an open-label, Phase II study to determine the safety and objective response rate of SGN-30 in 79 patients with refractory/recurrent HL (n = 38) or systemic ALCL (n = 41). Each course of SGN-30 comprised 6 weekly intravenous infusions, followed by a 2-week treatment-free period. Patients had received a median of 3 (range 1-5) prior regimens of chemotherapy or systemic therapy. The initial 40 patients received 6 mg/kg weekly; the latter 39 patients received 12 mg/kg weekly. In the ALCL group, two patients achieved a complete response and five additional patients achieved a partial response, with response durations ranging from 27 to 1460+ d. No objective responses were observed in the HL group; however, 11 patients (29%) had stable disease (duration 62-242 days). Although adverse events were common, most were mild or moderate, and no specific pattern of adverse events was observed in either disease group. These results demonstrate that weekly administration of SGN-30 is safe, with modest clinical activity in patients with ALCL.SGN-30, a chimeric anti-CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). We conducted an open-label, Phase II study to determine the safety and objective response rate of SGN-30 in 79 patients with refractory/recurrent HL (n = 38) or systemic ALCL (n = 41). Each course of SGN-30 comprised 6 weekly intravenous infusions, followed by a 2-week treatment-free period. Patients had received a median of 3 (range 1-5) prior regimens of chemotherapy or systemic therapy. The initial 40 patients received 6 mg/kg weekly; the latter 39 patients received 12 mg/kg weekly. In the ALCL group, two patients achieved a complete response and five additional patients achieved a partial response, with response durations ranging from 27 to 1460+ d. No objective responses were observed in the HL group; however, 11 patients (29%) had stable disease (duration 62-242 days). Although adverse events were common, most were mild or moderate, and no specific pattern of adverse events was observed in either disease group. These results demonstrate that weekly administration of SGN-30 is safe, with modest clinical activity in patients with ALCL. Summary SGN‐30, a chimeric anti‐CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). We conducted an open‐label, Phase II study to determine the safety and objective response rate of SGN‐30 in 79 patients with refractory/recurrent HL (n = 38) or systemic ALCL (n = 41). Each course of SGN‐30 comprised 6 weekly intravenous infusions, followed by a 2‐week treatment‐free period. Patients had received a median of 3 (range 1–5) prior regimens of chemotherapy or systemic therapy. The initial 40 patients received 6 mg/kg weekly; the latter 39 patients received 12 mg/kg weekly. In the ALCL group, two patients achieved a complete response and five additional patients achieved a partial response, with response durations ranging from 27 to 1460+ d. No objective responses were observed in the HL group; however, 11 patients (29%) had stable disease (duration 62–242 days). Although adverse events were common, most were mild or moderate, and no specific pattern of adverse events was observed in either disease group. These results demonstrate that weekly administration of SGN‐30 is safe, with modest clinical activity in patients with ALCL.
Author	Pinter‐Brown, Lauren Bosly, Andre Sievers, Eric L. Gopal, Ajay K. Kennedy, Dana Rosenblatt, Joseph D. Brice, Pauline Leonard, John P. Bartlett, Nancy L. Forero‐Torres, Andres Younes, Anas
Author_xml	– sequence: 1 givenname: Andres surname: Forero‐Torres fullname: Forero‐Torres, Andres – sequence: 2 givenname: John P. surname: Leonard fullname: Leonard, John P. – sequence: 3 givenname: Anas surname: Younes fullname: Younes, Anas – sequence: 4 givenname: Joseph D. surname: Rosenblatt fullname: Rosenblatt, Joseph D. – sequence: 5 givenname: Pauline surname: Brice fullname: Brice, Pauline – sequence: 6 givenname: Nancy L. surname: Bartlett fullname: Bartlett, Nancy L. – sequence: 7 givenname: Andre surname: Bosly fullname: Bosly, Andre – sequence: 8 givenname: Lauren surname: Pinter‐Brown fullname: Pinter‐Brown, Lauren – sequence: 9 givenname: Dana surname: Kennedy fullname: Kennedy, Dana – sequence: 10 givenname: Eric L. surname: Sievers fullname: Sievers, Eric L. – sequence: 11 givenname: Ajay K. surname: Gopal fullname: Gopal, Ajay K.
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21727413$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19466965$$D View this record in MEDLINE/PubMed
BookMark	eNqNkc1u1DAUhS1URKeFV0DegGCR9PondrIAaRhKZ1AFSMDachyn9ZDEQ5wRzY5H6DPyJDidYZDYUG_usfzdc617TtBR5zuLECaQknjO1ilhIkso4SSlAEUKUnJIbx6g2eHhCM0AQCYEeH6MTkJYAxAGGXmEjknBhShENkPtHH-61sHi1QqHYVuN2Nf488WHXz9vGeAXuhtclIu38dLOy5fYdXjpq6tvsTZju7n2rca-x2EMg22dwbrTm0aHIcpG91cWG9s0B_QxeljrJtgn-3qKvr47_7JYJpcfL1aL-WViMs4hYbmoOatsJevcWA4MciEArCxAUJ6VpLakqCpdMcOLUlBD8owLWrLCyJIyYKfo-c530_vvWxsG1bow_UR31m-DEpLLXBTkvyAFSkncYgSf7sFt2dpKbXrX6n5UfzYZgWd7QAejm7rXnXHhwFEiqeSERS7fcab3IfS2_msFagpXrdWUoZoyVFO46i5cdRNbX__TatygB-e7odeuuY_Bq53BD9fY8d6D1Zv3y0mx3wfXu5g
CODEN	BJHEAL
CitedBy_id	crossref_primary_10_1016_j_ctrv_2013_09_005 crossref_primary_10_1016_j_jconrel_2020_08_042 crossref_primary_10_1097_PPO_0b013e31826aef4a crossref_primary_10_1080_10428194_2017_1300898 crossref_primary_10_1002_ajh_25398 crossref_primary_10_1007_s12026_013_8464_1 crossref_primary_10_1080_10428194_2025_2545927 crossref_primary_10_1080_17474086_2017_1270202 crossref_primary_10_1080_17474086_2017_1350167 crossref_primary_10_1038_nrd3930 crossref_primary_10_1177_2040620712443076 crossref_primary_10_3390_hemato2010006 crossref_primary_10_1080_17474086_2019_1558399 crossref_primary_10_1186_1756_8722_5_S1_A2 crossref_primary_10_2217_phe_09_60 crossref_primary_10_1007_s11523_017_0535_0 crossref_primary_10_1182_blood_2015_05_641712 crossref_primary_10_1111_1346_8138_12346 crossref_primary_10_1007_s11899_016_0345_y crossref_primary_10_1016_j_heliyon_2023_e21776 crossref_primary_10_1111_bjh_15658 crossref_primary_10_1185_03007995_2015_1030378 crossref_primary_10_1634_theoncologist_2011_0258 crossref_primary_10_1517_17460441_2012_727392 crossref_primary_10_2745_dds_32_126 crossref_primary_10_1007_s40259_013_0077_7 crossref_primary_10_1684_bdc_2013_1778 crossref_primary_10_1007_s11899_014_0220_7 crossref_primary_10_1182_bloodadvances_2021004453C crossref_primary_10_1080_08998280_2015_11929282 crossref_primary_10_2217_ijh_13_59 crossref_primary_10_1517_14712598_2011_560569 crossref_primary_10_1038_s41392_020_0113_2 crossref_primary_10_1007_s12185_014_1522_1 crossref_primary_10_1007_s40257_018_0402_5 crossref_primary_10_1586_17474086_2015_1044432 crossref_primary_10_1155_2011_865870 crossref_primary_10_3390_cancers11081071 crossref_primary_10_3390_cancers10060204 crossref_primary_10_1007_s11899_012_0126_1 crossref_primary_10_1016_j_beha_2013_04_005 crossref_primary_10_14694_EdBook_AM_2012_32_83 crossref_primary_10_1182_blood_2013_10_492223 crossref_primary_10_1200_JCO_2014_60_3787 crossref_primary_10_1016_j_blre_2010_08_003 crossref_primary_10_1111_j_1600_0463_2011_02811_x crossref_primary_10_1007_s00253_011_3335_y crossref_primary_10_1016_j_ymthe_2017_06_026 crossref_primary_10_1002_pbc_27094 crossref_primary_10_3390_cancers11030394 crossref_primary_10_1007_s11899_010_0053_y crossref_primary_10_1517_13543784_2011_546562 crossref_primary_10_1038_modpathol_2010_224 crossref_primary_10_1038_nbt_2289 crossref_primary_10_1016_j_ctrc_2015_06_002 crossref_primary_10_2174_0929867324666171006144725 crossref_primary_10_1007_s12325_017_0519_6 crossref_primary_10_1586_era_11_4 crossref_primary_10_1177_1758835920962997 crossref_primary_10_1002_hon_2014 crossref_primary_10_1038_bmt_2013_226 crossref_primary_10_1111_bjh_13578 crossref_primary_10_1200_JCO_2011_38_0402 crossref_primary_10_1186_1746_1596_7_128 crossref_primary_10_3109_10428194_2011_574761 crossref_primary_10_1155_2015_968212 crossref_primary_10_3390_cancers13236003 crossref_primary_10_1080_14740338_2016_1179277 crossref_primary_10_3390_cancers14030626 crossref_primary_10_1146_annurev_med_050311_201823 crossref_primary_10_1185_03007995_2015_1008131 crossref_primary_10_1016_j_pharmthera_2021_107892 crossref_primary_10_1038_s41417_021_00295_8 crossref_primary_10_1155_2011_439456 crossref_primary_10_1053_j_seminhematol_2013_02_002 crossref_primary_10_1016_j_clml_2018_03_012 crossref_primary_10_2217_fon_11_79 crossref_primary_10_1016_j_critrevonc_2015_08_014 crossref_primary_10_1111_j_1365_2141_2011_08651_x crossref_primary_10_1016_j_ctrv_2014_08_001 crossref_primary_10_1172_JCI61205 crossref_primary_10_1038_s41408_018_0168_2 crossref_primary_10_1111_j_1349_7006_2009_01354_x crossref_primary_10_1586_17474086_2013_814434 crossref_primary_10_1007_s13554_013_0008_7 crossref_primary_10_1517_14656566_2011_565332 crossref_primary_10_1182_blood_2014_06_537514 crossref_primary_10_1016_j_beha_2010_07_001 crossref_primary_10_14712_fb2020066010017 crossref_primary_10_1182_blood_2016_04_709477 crossref_primary_10_1177_2040620710387980 crossref_primary_10_1007_s40259_013_0068_8 crossref_primary_10_2217_ijh_15_27 crossref_primary_10_1038_bcj_2012_8 crossref_primary_10_1053_j_semdp_2011_03_002 crossref_primary_10_1158_1078_0432_CCR_12_3064 crossref_primary_10_1038_nrclinonc_2012_156 crossref_primary_10_3109_08880018_2011_613094 crossref_primary_10_1016_j_critrevonc_2012_06_004 crossref_primary_10_1517_14712598_2012_673578 crossref_primary_10_1002_jps_23761 crossref_primary_10_1007_s11899_012_0137_y crossref_primary_10_3390_cancers13010144 crossref_primary_10_1111_bjh_18841 crossref_primary_10_3389_fonc_2018_00193 crossref_primary_10_1189_jlb_2MR1015_468R crossref_primary_10_4137_CMO_S6637 crossref_primary_10_1016_j_beha_2011_03_002 crossref_primary_10_1111_bjh_13152 crossref_primary_10_1016_j_biomaterials_2013_07_068 crossref_primary_10_21320_2500_2139_2016_9_4_398_405 crossref_primary_10_1097_CCO_0b013e32834bb8a7 crossref_primary_10_3390_cancers17030496 crossref_primary_10_1158_1078_0432_CCR_11_0488 crossref_primary_10_1172_JCI94306 crossref_primary_10_1517_17425255_2015_1007950 crossref_primary_10_1186_s13045_018_0601_9 crossref_primary_10_1016_j_blre_2014_09_011 crossref_primary_10_1111_bjh_13265 crossref_primary_10_1080_17474086_2025_2492936 crossref_primary_10_1016_S0001_7310_09_73165_5 crossref_primary_10_1016_S0140_6736_17_31473_3 crossref_primary_10_1056_NEJMoa1002965 crossref_primary_10_1007_s11899_010_0065_7 crossref_primary_10_1093_ajhp_zxz202 crossref_primary_10_1124_dmd_114_058586 crossref_primary_10_1111_imr_12248 crossref_primary_10_1016_j_hoc_2013_10_004 crossref_primary_10_3390_cancers10090339 crossref_primary_10_1158_1078_0432_CCR_11_1425 crossref_primary_10_3390_cancers16203489 crossref_primary_10_1016_j_blre_2022_100949 crossref_primary_10_2146_ajhp110608 crossref_primary_10_3109_10428194_2012_744453 crossref_primary_10_1517_14712598_2012_718328 crossref_primary_10_1016_j_hoc_2013_10_009 crossref_primary_10_1158_1078_0432_CCR_12_0290 crossref_primary_10_1182_blood_2019001821 crossref_primary_10_2217_imt_11_15 crossref_primary_10_1007_s11899_020_00561_w crossref_primary_10_1158_1078_0432_CCR_09_1995 crossref_primary_10_1111_ejh_12347 crossref_primary_10_1517_13543784_2011_542147 crossref_primary_10_1007_s11864_014_0275_7 crossref_primary_10_1177_2040620711408491 crossref_primary_10_1016_j_clml_2012_12_008 crossref_primary_10_1111_bjh_15152 crossref_primary_10_1586_ehm_11_55 crossref_primary_10_1080_17474086_2017_1268046 crossref_primary_10_14694_EdBook_AM_2015_35_e468 crossref_primary_10_1007_s00761_009_1765_2 crossref_primary_10_1007_s12185_014_1521_2 crossref_primary_10_1517_14656566_2010_515979 crossref_primary_10_3390_ijms21062081 crossref_primary_10_1093_abt_tbaf002 crossref_primary_10_1111_j_1525_1470_2011_01465_x crossref_primary_10_1038_bcj_2017_85 crossref_primary_10_1517_14728214_2010_505602 crossref_primary_10_1016_j_bbmt_2011_08_012 crossref_primary_10_1517_14712598_2012_670216 crossref_primary_10_3322_caac_21589 crossref_primary_10_2147_OTT_S193951
Cites_doi	10.3109/10428199809059232 10.1182/blood-2003-02-0515 10.1182/blood-2002-11-3507 10.1182/blood-2001-12-0295 10.1200/JCO.2006.07.8972 10.1182/blood-2007-07-099317 10.1016/0140-6736(92)91135-U 10.1038/sj.leu.2403884 10.1016/0092-8674(92)90180-K 10.1182/blood.V85.1.1.bloodjournal8511 10.4049/jimmunol.169.5.2451 10.1200/JCO.1999.17.4.1244 10.1182/blood.V93.11.3913 10.3109/10428199609052421 10.1200/JCO.1989.7.11.1630 10.1200/JCO.2005.09.098 10.1128/MCB.17.3.1535 10.4049/jimmunol.172.4.2186 10.4065/81.3.419
ContentType	Journal Article
Copyright	2009 Blackwell Publishing Ltd 2009 INIST-CNRS
Copyright_xml	– notice: 2009 Blackwell Publishing Ltd – notice: 2009 INIST-CNRS
DBID	AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 H94 7X8
DOI	10.1111/j.1365-2141.2009.07740.x
DatabaseName	CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts MEDLINE - Academic
DatabaseTitleList	MEDLINE CrossRef AIDS and Cancer Research Abstracts MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1365-2141
EndPage	179
ExternalDocumentID	19466965 21727413 10_1111_j_1365_2141_2009_07740_x BJH7740
Genre	article Multicenter Study Clinical Trial, Phase II Journal Article
GroupedDBID	--- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1KJ 1OB 1OC 23N 24P 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6J9 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8F7 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAYEP AAZKR ABCQN ABCUV ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHEFC AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EGARE EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IH2 IHE IX1 J0M J5H K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 V8K V9Y VH1 W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY AIQQE CITATION O8X IQODW CGR CUY CVF ECM EIF NPM 7T5 H94 7X8
ID	FETCH-LOGICAL-c5440-386f43ded7f8ce403086600e7906245b1fe19ddad3c49b62c185462b39c7b2303
IEDL.DBID	WIN
ISICitedReferencesCount	192
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000267657300006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0007-1048 1365-2141
IngestDate	Thu Oct 02 10:42:34 EDT 2025 Fri Jul 11 07:02:43 EDT 2025 Thu Apr 03 07:00:10 EDT 2025 Mon Jul 21 09:17:22 EDT 2025 Tue Nov 18 21:56:12 EST 2025 Sat Nov 29 03:23:21 EST 2025 Wed Jan 22 17:06:53 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	2
Keywords	Hematology anti-CD30 antibody Anaplastic cell lymphoma Hodgkin disease Malignant hemopathy Large cell lymphoma Monoclonal antibody Non Hodgkin lymphoma Treatment Lymphoproliferative syndrome Phase II trial anaplastic large cell lymphoma Anaplastic lymphoma kinase Cancer Hodgkin lymphoma
Language	English
License	CC BY 4.0
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c5440-386f43ded7f8ce403086600e7906245b1fe19ddad3c49b62c185462b39c7b2303
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1
OpenAccessLink	https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2141.2009.07740.x
PMID	19466965
PQID	20221007
PQPubID	23462
PageCount	9
ParticipantIDs	proquest_miscellaneous_67478691 proquest_miscellaneous_20221007 pubmed_primary_19466965 pascalfrancis_primary_21727413 crossref_primary_10_1111_j_1365_2141_2009_07740_x crossref_citationtrail_10_1111_j_1365_2141_2009_07740_x wiley_primary_10_1111_j_1365_2141_2009_07740_x_BJH7740
PublicationCentury	2000
PublicationDate	July 2009
PublicationDateYYYYMMDD	2009-07-01
PublicationDate_xml	– month: 07 year: 2009 text: July 2009
PublicationDecade	2000
PublicationPlace	Oxford, UK
PublicationPlace_xml	– name: Oxford, UK – name: Oxford – name: England
PublicationTitle	British journal of haematology
PublicationTitleAlternate	Br J Haematol
PublicationYear	2009
Publisher	Blackwell Publishing Ltd Blackwell
Publisher_xml	– name: Blackwell Publishing Ltd – name: Blackwell
References	2006; 81 1995; 85 2005; 19 2002; 62 1999; 17 1989; 7 2002; 169 2002; 100 2004; 172 2002; 8 1997; 17 1992; 339 1992; 68 1999; 93 2008; 111 2003; 102 1998; 31 2007; 25 1996; 20 2005; 23 e_1_2_9_20_1 e_1_2_9_11_1 e_1_2_9_22_1 Wahl A.F. (e_1_2_9_23_1) 2002; 62 e_1_2_9_10_1 e_1_2_9_13_1 e_1_2_9_24_1 e_1_2_9_12_1 e_1_2_9_8_1 e_1_2_9_7_1 Bartlett N.L. (e_1_2_9_4_1) 2002; 100 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_3_1 Falini B. (e_1_2_9_14_1) 1999; 93 e_1_2_9_2_1 e_1_2_9_9_1 e_1_2_9_15_1 Schnell R. (e_1_2_9_21_1) 2002; 8 e_1_2_9_17_1 e_1_2_9_16_1 e_1_2_9_19_1 e_1_2_9_18_1
References_xml	– volume: 17 start-page: 1244 year: 1999 end-page: 1253 article-title: Report of an international workshop to standardize response criteria for non‐Hodgkin’s lymphomas. NCI Sponsored International Working Group publication-title: Journal of Clinical Oncology – volume: 85 start-page: 1 year: 1995 end-page: 14 article-title: CD30 (Ki‐1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy publication-title: Blood – volume: 19 start-page: 1648 year: 2005 end-page: 1655 article-title: Signaling via the anti‐CD30 mAb SGN‐30 sensitizes Hodgkin’s disease cells to conventional chemotherapeutics publication-title: Leukemia – volume: 169 start-page: 2451 year: 2002 end-page: 2459 article-title: TCR‐independent CD30 signaling selectively induces IL‐13 production via a TNF receptor‐associated factor/p38 mitogen‐activated protein kinase‐dependent mechanism publication-title: Journal of Immunology – volume: 17 start-page: 1535 year: 1997 end-page: 1542 article-title: Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2 publication-title: Molecular and Cellular Biology – volume: 339 start-page: 1195 year: 1992 end-page: 1196 article-title: Response of refractory Hodgkin’s disease to monoclonal anti‐CD30 immunotoxin publication-title: Lancet – volume: 62 start-page: 3736 year: 2002 end-page: 3742 article-title: The anti‐CD30 monoclonal antibody SGN‐30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin’s disease publication-title: Cancer Research – volume: 31 start-page: 385 year: 1998 end-page: 392 article-title: Anti‐CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin’s disease publication-title: Leukemia and Lymphoma – volume: 93 start-page: 2697 year: 1999 end-page: 2706 article-title: ALK+ lymphoma: clinico‐pathological findings and outcome publication-title: Blood – volume: 20 start-page: 397 year: 1996 end-page: 409 article-title: CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells publication-title: Leukemia and Lymphoma – volume: 172 start-page: 2186 year: 2004 end-page: 2193 article-title: Extremely rapid and intense induction of apoptosis in human eosinophils by anti‐CD30 antibody treatment in vitro publication-title: Journal of Immunology – volume: 23 start-page: 4669 year: 2005 end-page: 4678 article-title: Treatment of refractory Hodgkin’s lymphoma patients with an iodine‐131‐labeled murine anti‐CD30 monoclonal antibody publication-title: Journal of Clinical Oncology – volume: 93 start-page: 3913 year: 1999 end-page: 3921 article-title: Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma publication-title: Blood – volume: 100 start-page: 362a year: 2002 end-page: 363a article-title: Phase I study of SGN‐30, a chimeric monoclonal antibody (mAb), in patients with refractory or recurrent CD30+ hematologic malignancies publication-title: Blood – volume: 25 start-page: 2764 year: 2007 end-page: 2769 article-title: Phase I/II study of an anti‐CD30 monoclonal antibody (MDX‐060) in Hodgkin’s lymphoma and anaplastic large‐cell lymphoma publication-title: Journal of Clinical Oncology – volume: 68 start-page: 421 year: 1992 end-page: 427 article-title: Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease publication-title: Cell – volume: 100 start-page: 3101 year: 2002 end-page: 3107 article-title: Phase 1 trial of the novel bispecific molecule H22xKi‐4 in patients with refractory Hodgkin lymphoma publication-title: Blood – volume: 111 start-page: 1848 year: 2008 end-page: 1854 article-title: A phase 1 multidose study of SGN‐30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies publication-title: Blood – volume: 81 start-page: 419 year: 2006 end-page: 426 article-title: Management of Hodgkin lymphoma publication-title: Mayo Clinic Proceedings – volume: 8 start-page: 1779 year: 2002 end-page: 1786 article-title: A Phase I study with an anti‐CD30 ricin A‐chain immunotoxin (Ki‐4.dgA) in patients with refractory CD30+ Hodgkin’s and non‐Hodgkin’s lymphoma publication-title: Clinical Cancer Research – volume: 102 start-page: 1019 year: 2003 end-page: 1027 article-title: MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival publication-title: Blood – volume: 102 start-page: 3737 year: 2003 end-page: 3742 article-title: The human anti‐CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma publication-title: Blood – volume: 7 start-page: 1630 year: 1989 end-page: 1636 article-title: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting publication-title: Journal of Clinical Oncology – ident: e_1_2_9_18_1 doi: 10.3109/10428199809059232 – ident: e_1_2_9_7_1 doi: 10.1182/blood-2003-02-0515 – ident: e_1_2_9_24_1 doi: 10.1182/blood-2002-11-3507 – ident: e_1_2_9_6_1 doi: 10.1182/blood-2001-12-0295 – volume: 100 start-page: 362a year: 2002 ident: e_1_2_9_4_1 article-title: Phase I study of SGN‐30, a chimeric monoclonal antibody (mAb), in patients with refractory or recurrent CD30+ hematologic malignancies publication-title: Blood – ident: e_1_2_9_3_1 doi: 10.1200/JCO.2006.07.8972 – ident: e_1_2_9_5_1 doi: 10.1182/blood-2007-07-099317 – ident: e_1_2_9_12_1 doi: 10.1016/0140-6736(92)91135-U – volume: 93 start-page: 2697 year: 1999 ident: e_1_2_9_14_1 article-title: ALK+ lymphoma: clinico‐pathological findings and outcome publication-title: Blood – ident: e_1_2_9_8_1 doi: 10.1038/sj.leu.2403884 – ident: e_1_2_9_11_1 doi: 10.1016/0092-8674(92)90180-K – ident: e_1_2_9_13_1 doi: 10.1182/blood.V85.1.1.bloodjournal8511 – ident: e_1_2_9_17_1 doi: 10.4049/jimmunol.169.5.2451 – volume: 8 start-page: 1779 year: 2002 ident: e_1_2_9_21_1 article-title: A Phase I study with an anti‐CD30 ricin A‐chain immunotoxin (Ki‐4.dgA) in patients with refractory CD30+ Hodgkin’s and non‐Hodgkin’s lymphoma publication-title: Clinical Cancer Research – ident: e_1_2_9_9_1 doi: 10.1200/JCO.1999.17.4.1244 – volume: 62 start-page: 3736 year: 2002 ident: e_1_2_9_23_1 article-title: The anti‐CD30 monoclonal antibody SGN‐30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin’s disease publication-title: Cancer Research – ident: e_1_2_9_15_1 doi: 10.1182/blood.V93.11.3913 – ident: e_1_2_9_16_1 doi: 10.3109/10428199609052421 – ident: e_1_2_9_19_1 doi: 10.1200/JCO.1989.7.11.1630 – ident: e_1_2_9_22_1 doi: 10.1200/JCO.2005.09.098 – ident: e_1_2_9_10_1 doi: 10.1128/MCB.17.3.1535 – ident: e_1_2_9_20_1 doi: 10.4049/jimmunol.172.4.2186 – ident: e_1_2_9_2_1 doi: 10.4065/81.3.419
SSID	ssj0013051
Score	2.4185123
Snippet	Summary SGN‐30, a chimeric anti‐CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic... SGN‐30, a chimeric anti‐CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large... SGN-30, a chimeric anti-CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large... SummarySGN-30, a chimeric anti-CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic...
SourceID	proquest pubmed pascalfrancis crossref wiley
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	171
SubjectTerms	Adult Aged anaplastic large cell lymphoma anaplastic lymphoma kinase Antibodies, Anti-Idiotypic - blood Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antineoplastic Agents - administration & dosage anti‐CD30 antibody Biological and medical sciences Chimerin Proteins - blood Dose-Response Relationship, Drug Female Hematologic and hematopoietic diseases Hodgkin Disease - therapy Hodgkin lymphoma Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, Large-Cell, Anaplastic - drug therapy Male Medical sciences Middle Aged monoclonal antibody Young Adult
Title	A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
URI	https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2141.2009.07740.x https://www.ncbi.nlm.nih.gov/pubmed/19466965 https://www.proquest.com/docview/20221007 https://www.proquest.com/docview/67478691
Volume	146
WOSCitedRecordID	wos000267657300006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVWIB databaseName: Wiley Online Library - Journals customDbUrl: eissn: 1365-2141 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0013051 issn: 0007-1048 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1365-2141 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0013051 issn: 0007-1048 databaseCode: WIN dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwEB7BghAS4v0Ij-IDBzgEJbHjxMeyS2kRVCtgRW-R7dhQ0SZVu4vgxk_gN_JLmEmyXSIt0gpxihPZiTOesT9nJvMBPOHScV5GNsyVMCGuUCY0QmWhioyPlOeI8kVDNpFNp_lspva7-Cf6F6bND7H94EaW0czXZODabPpG3kRoxSLu0k4ikomeE57ES0Rm8HEyPXEoRGlHnpfhzCPyflDPqTfqrVRXVnqDQvMt28VpcLSPbpvlaXTtf77YdbjagVQ2bLXqBpxz1U249LZzw9-C5ZDtf8blj00mrMlPy2rP3r-a_vrxk0fsKQ7WHIu7e3iyHJpnbF6xcV1--oLHxXdUn3qpWb1mbRbpuWW60itE8fg0tqDIdEbuhG3V23Awevlhdxx2vA2hTclVzHPpBS9dmfncOkEZcSTiKpdRTmSRmti7WJWlLrkVysjEImYQMjFc2czglojfgZ2qrtw9YDj_qMzoJFEWgZtzKkl1JBHmCC9yz0UA2fEYFbZLak7cGovij80NSrMgaRLlpioaaRbfAoi3LVdtYo8ztBn01GDbkFi-EJrxAB4f60WBZkrC0pWrjzZ4myShgJS_15DEZCBVHMDdVqFOukUcAEqmAchGb87c3-LF6zGV7v9rwwdwufWeUXjyQ9g5XB-5R3DRfj2cb9YDOJ_N8gFc2Hs3OngzaOztNw6QIVA
linkProvider	Wiley-Blackwell
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwEB6hFgESovyWQGl94ACHoCR2nPi49IddaKNKFNFbFDs2rLqbrHbbCm48As_IkzCTpFsiFalCnOJIduKMZ-zPnsl8AC-5tJyXgfFTJbSPK5T2tVCJrwLtAuU4onzRkE0kWZYeH6vDjg6I_oVp80MsD9zIMpr5mgycDqT7Vt6EaIUi7PJOIpQJ3iCgXBWIO4jH4fMou3QpBHFHn5fg3CPSfljPlU_qrVV3Z8UCxeZavourAGkf3zYL1N7af_20-3Cvw6ls0CrWA7hhq4dw66DzxD-C6YAdfsUVkI1GrElRy2rHPr7Lfv34yQP2CsdrjMXtHbyZDvRrNq7YsC6_nOB18h01qJ4WrJ6zNpH02LCiKmYI5PFtbELB6Yw8Csuqj-HT3u7R9tDvqBt8E5O3mKfSCV7aMnGpsYKS4kiEVjahtMgi1qGzoSrLouRGKC0jg7BByEhzZRKNuyL-BFaqurJPgeEUpBJdRJEyiN2sVVFcBBKRjnAidVx4kFwMUm66vOZErzHJ_9jfoDRzkiaxbqq8kWb-zYNw2XLW5va4RpvNnh4sGxLRF6Iz7sHWhWLkaKkkrKKy9dkCHxNFFJPy9xqSyAykCj1YbzXqsltEA6Bk7IFsFOfa_c3fvh9S6dm_NtyC28Ojg_18f5R9eA53WmcaRStvwMrp_My-gJvm_HS8mG825vYbUx8i5g
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1fb9MwED-hDk1IaPwdhD-bH3iAh6Akdpz4sayUFkZVAZP2FsWODRVtUrXbBG98BD4jn4S7JOuINKQJ8RRHsh3nfGf_nLvcD-AZl5bzIjB-qoT2cYfSvhYq8VWgXaAcR5QvarKJZDJJj4_VtKUDon9hmvwQmw9uZBn1ek0GbpeF61p5HaIVirDNO4lQJniJgHJLEKdMD7YGH4ZHhxdOhSBuCfQSXH1E2g3subSvzm51c5mvUXCuYby4DJJ2EW69RQ1v_deXuw07LVJl_Ua17sA1W96F7fetL_4eLPps-gX3QDYeszpJLasc-_hm8uvHTx6w5zhjMyweDPBm0dcv2Kxko6r4_BWv8--oQ9UiZ9WKNamkZ4blZb5EKI9PY3MKT2fkU9hUvQ9Hw9efDkZ-S97gm5j8xTyVTvDCFolLjRWUFkciuLIJJUYWsQ6dDVVR5AU3QmkZGQQOQkaaK5NoPBfxXeiVVWkfAsNFSCU6jyJlEL1Zq6I4DyRiHeFE6rjwIDmfpMy0mc2JYGOe_XHCQWlmJE3i3VRZLc3smwfhpuWyye5xhTZ7HT3YNCSqL8Rn3IP9c8XI0FZJWHlpq9M1dhNFFJXy9xqS6AykCj140GjUxbCICEDJ2ANZK86Vx5u9ejui0qN_bbgP29PBMDscT949hhuNN43ClZ9A72R1ap_CdXN2Mluv9lp7-w1TnCOP
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Phase+II+study+of+SGN-30+%28anti-CD30+mAb%29+in+Hodgkin+lymphoma+or+systemic+anaplastic+large+cell+lymphoma&rft.jtitle=British+journal+of+haematology&rft.au=Forero-Torres%2C+Andres&rft.au=Leonard%2C+John+P&rft.au=Younes%2C+Anas&rft.au=Rosenblatt%2C+Joseph+D&rft.date=2009-07-01&rft.eissn=1365-2141&rft.volume=146&rft.issue=2&rft.spage=171&rft_id=info:doi/10.1111%2Fj.1365-2141.2009.07740.x&rft_id=info%3Apmid%2F19466965&rft.externalDocID=19466965
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1048&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1048&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1048&client=summon